Chemically Modified Tetracycline Derivatives for Dry AMD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments are ineffective for the 90% of patients with dry age-related macular degeneration (AMD), as there is no established therapy or preventative method available, and existing anti-vascular endothelial growth factor therapies only address the 10% with neovascular AMD.
Innovation Solution
Chemically modified tetracycline (CMT) derivatives, such as doxycycline, are administered at subantimicrobial doses to inhibit inflammation and oxidative stress, lacking antimicrobial activity to prevent activation of gut microbiome inflammatory cells and reduce progression of geographic atrophy in AMD, with a focus on non-exudative AMD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-vascular endothelial growth factor therapies are used, then treatment effectiveness is improved for neovascular AMD, but applicability is reduced to only 10% of patients
Solution Approach 1:
The patent develops a therapeutic composition based on tetracycline derivatives that can treat both wet and dry AMD, making the treatment universally applicable to all AMD patients regardless of disease subtype, thereby resolving the limitation of VEGF therapies being restricted to only neovascular AMD
2Reliability
If tetracycline derivatives are administered at antimicrobial doses, then anti-inflammatory activity is improved, but harmful effects are increased due to gut microbiome disruption
Solution Approach 1:
The patent changes the dosage parameter from conventional antimicrobial doses to subantimicrobial doses of tetracycline derivatives, which maintains anti-inflammatory and antioxidant benefits while eliminating harmful effects on gut microbiome, thereby resolving the contradiction between therapeutic effectiveness and safety
3Reliability
If conventional doses of tetracycline are used, then anti-inflammatory effects are improved, but loss of substance is increased due to antimicrobial activity depleting beneficial gut bacteria
Solution Approach 1:
The patent extracts and utilizes only the anti-inflammatory and antioxidant properties of tetracycline derivatives by administering them at subantimicrobial doses, effectively separating the therapeutic benefits from the harmful antimicrobial effects that deplete beneficial gut bacteria
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Subantimicrobial doxycycline treatment demonstrates a significant reduction in the progression of geographic atrophy lesions, slowing the disease progression by inhibiting inflammatory pathways and reducing retinal degeneration, as shown in clinical studies, offering a novel therapeutic approach for dry AMD.
Implementation Method 1
comprise a chemical structure sufficient to chelate Zn2+
Implementation Method 2
the phenol ring can comprise a diethylamino group to enhance scavenging of reactive oxygen species
Data Source
AI summary
Provided are chemically modified tetracycline (CMT) derivatives for the treatment of non-exudative macular degeneration. The CMT derivatives lack antimicrobial activity, include a phenol ring, and a chemical structure sufficient to chelate Zn2+. Methods of inhibiting and/or minimizing inflammation in a subject, including administering to the subject a dose of a CMT derivative, are also provided. Methods of treating non-exudative age-related macular degeneration (AMD) are provided.